Xanthigen and Its Impact on Weight and Metabolic Health
ConditionObesity & Overweight
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-50
SponsorUniversidad Católica San Antonio de Murcia
About this trial
Randomized, controlled, triple-blind clinical trial with three parallel arms based on the product consumed (low-dose experimental product, high-dose experimental product, and placebo product) and conducted at a single center to measure the efficacy of a product (Xanthigen®) on overweight or obesity during 16 weeks of consumption.
Eligibility criteria
Qualifiers
The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations.
Participants must be between 20 and 50 years of age at the time of consent.
The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results.
Participants must have a BMI between 27 and 29.9 kg/cm2.
Disqualifiers
Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions.
Fasting blood sugar levels greater than 125 mg/dL and/or total cholesterol levels greater than or equal to 240 mg/dL.
Blood pressure levels below 90/140 mm Hg (diastolic/systolic).
Chronic intake of medications/dietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study.
Trial design
Treatments tested in this trial
- Experimental group: Xanthigen®
- Control product
Treatment groups
180 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov